Article

NSD2 maintains lineage plasticity and castration-resistance in neuroendocrine prostate cancer

2023-07-19

Abstract excerpt

<h4>Summary</h4> The clinical use of potent androgen receptor (AR) inhibitors has promoted the emergence of novel subtypes of metastatic castration-resistant prostate cancer (mCRPC), including neuroendocrine prostate cancer (CRPC-NE), which is highly aggressive and lethal 1 . These mCRPC subtypes display increased lineage plasticity and often lack AR expression 2–5 . Here we show that neuroendocrine differentia...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0874dcd8-4bf0-58f0-8e18-06a2a451cc71
DOI: 10.1101/2023.07.18.549585

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

NSD2 maintains lineage plasticity and castration-resistance in neuroendocrine prostate cancerDOI 10.1101/2023.07.18.549585Read

Defined cellular reprogramming of androgen receptor-active prostate cancer to neuroendocrine prostate cancerSemantic proximity Read

Targeting Key Players of Neuroendocrine Differentiation in Prostate CancerSemantic proximity Read

Role of transcription factors and chromatin modifiers in driving lineage reprogramming in treatment-induced neuroendocrine prostate cancerSemantic proximity Read

Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer.Semantic proximity Read

Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1Semantic proximity Read

Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypesSemantic proximity Read

Neuroendocrine transdifferentiation in human cancer: molecular mechanisms and therapeutic targetsSemantic proximity Read

DPYSL5 is highly expressed in treatment-induced neuroendocrine prostate cancer and promotes lineage plasticity via EZH2/PRC2Semantic proximity Read

Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate CancerSemantic proximity Read

NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesisSemantic proximity Read

A novel role for Neurog2 in MYCN driven neuroendocrine plasticity of prostate cancerSemantic proximity Read

Epigenetic remodeling and 3D chromatin reorganization governed by NKX2-1 drive neuroendocrine prostate cancerSemantic proximity Read